AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39472511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of autologous platelet-rich plasma (PRP)
Number of subjects: 80
Study 39472511 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP infusion)
Number of subjects: 80
Study 39472768 — intervention group
Group type: EXPERIMENTAL
Intervention: PRX004 (0.1, 0.3, 1, 3, 10 or 30 mg/kg), administered intravenously every 28 days for 3 months
Number of subjects: 21
Study 39472768 — intervention group
Group type: EXPERIMENTAL
Intervention: PRX004 (≥3 mg/kg for ≥9 months)
Number of subjects: 21
Study 39472831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine misoprostol (400 mg) + oxytocin
Number of subjects: 192
Study 39472831 — intervention group
Group type: COMPARATOR
Intervention: Sublingual misoprostol (400 mg) + oxytocin
Number of subjects: 192
Study 39472953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty (Wolverine™)
Number of subjects: 250
Study 39472953 — intervention group
Group type: COMPARATOR
Intervention: Non-compliant balloon
Number of subjects: 250
Study 39472975 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI) including health coaching, physician training, medication subsidy, and case review meetings
Number of subjects: 896
Study 39472975 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 896
Study 39473003 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% hyaluronic acid gel-impregnated dental floss
Number of subjects: 0
Study 39473003 — intervention group
Group type: COMPARATOR
Intervention: Dental floss alone
Number of subjects: 0
Study 39473014 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 16
Study 39473014 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed precision doses of tDCS
Number of subjects: 16
Study 39473017 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients (APACHE II score ≥ 15, invasive pulmonary aspergillosis, therapeutic dose of anticoagulants, extracorporeal membrane oxygenation, continuous renal replacement therapy)
Number of subjects: 931
Study 39473017 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion not related to bleeding
Number of subjects: 931
Study 39473051 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks
Number of subjects: 0
Study 39473051 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study 39473051 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline gut fungal signatures
Number of subjects: 0
Study 39473059 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiation therapy and docetaxel (45 Gy radiotherapy in 25 fractions over 5 weeks, weekly dose-escalated docetaxel up to 30 mg/m²)
Number of subjects: 25
Study 39473059 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiation therapy and docetaxel
Number of subjects: 25
Study 39473076 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizanlizumab (5 mg/kg)
Number of subjects: 112
Study 39473159 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk individuals (HR)
Number of subjects: 96
Study 39473159 — intervention group
Group type: COMPARATOR
Intervention: Recently detoxified alcohol-dependent (AD)
Number of subjects: 96
Study 39473159 — intervention group
Group type: COMPARATOR
Intervention: Low risk (LR)
Number of subjects: 96
Study 39473159 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA levels in the ACC
Number of subjects: 96
Study 39473159 — intervention group
Group type: COMPARATOR
Intervention: Abstinence duration in AD
Number of subjects: 96
Study 39473396 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels in children with nocturnal enuresis
Number of subjects: 120
Study 39473396 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D levels in healthy control children
Number of subjects: 120
Study 39473396 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Vitamin D levels with nocturnal urine osmolality
Number of subjects: 120
Study 39473503 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase laparoscopic endometrioma surgery
Number of subjects: 55
Study 39473503 — intervention group
Group type: COMPARATOR
Intervention: Luteal phase laparoscopic endometrioma surgery
Number of subjects: 55
Study 39473704 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen paste injection
Number of subjects: 14
Study 39474371 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic carotid artery stenosis (CAS) patients
Number of subjects: 195
Study 39474371 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic carotid artery stenosis (CAS) patients with SBI
Number of subjects: 195
Study 39474441 — intervention group
Group type: EXPERIMENTAL
Intervention: EGD in patients aged 61-70 years
Number of subjects: 1003
Study 39474441 — intervention group
Group type: COMPARATOR
Intervention: EGD in patients aged 51-60 years
Number of subjects: 1003
Study 39474441 — intervention group
Group type: COMPARATOR
Intervention: EGD in patients aged 41-50 years
Number of subjects: 1003
Study 39474484 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39474711 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative lymphopaenia on postoperative day 1 (POD1)
Number of subjects: 1207
Study 39474711 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery duration > 200 minutes
Number of subjects: 1207
Study 39474711 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA score IV
Number of subjects: 1207
Study 39474711 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in postoperative lymphocyte counts (LC) over time
Number of subjects: 1207
Study 39474711 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lymphocyte counts (LC)
Number of subjects: 1207
Study 39474720 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg/day
Number of subjects: 261
Study 39474720 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg/day
Number of subjects: 261
Study 39474765 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Radial Access (DRA)
Number of subjects: 850
Study 39474765 — intervention group
Group type: COMPARATOR
Intervention: Traditional Radial Access (TRA)
Number of subjects: 850
Study 39474856 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling device offered by a midwife
Number of subjects: 600
Study 39474856 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling device
Number of subjects: 600
Study 39474856 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires on socio-economic environment and motivational factors
Number of subjects: 600
Study 39474856 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with a sub-group
Number of subjects: 600
Study 39474983 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve edge-to-edge repair (T-TEER)
Number of subjects: 1230
Study 39475112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir treatment
Number of subjects: 501
Study 39475143 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (up to 64 Units)
Number of subjects: 730
Study 39475143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study 39475399 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid-valve replacement and medical therapy
Number of subjects: 400
Study 39475399 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (control group)
Number of subjects: 400
Study 39475416 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced tension-line (RTL) suture with 4 : 1 small-bite closure with polypropylene sutures (RTL group)
Number of subjects: 160
Study 39475416 — intervention group
Group type: COMPARATOR
Intervention: 4 : 1 small-bite closure with polydioxanone suture alone (PDS group)
Number of subjects: 160
Study 39475418 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib + endocrine therapy (ET) in first-line (1L) setting
Number of subjects: 1250
Study 39475418 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib + endocrine therapy (ET) in second-line or later (≥2L) setting
Number of subjects: 1250
Study 39475817 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin, dosage and duration not available
Number of subjects: 0
Study 39475817 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 39475834 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-point serratus anterior plane block (SAPB)
Number of subjects: 60
Study 39475834 — intervention group
Group type: COMPARATOR
Intervention: Single-point serratus anterior plane block (SAPB)
Number of subjects: 60
Study 39475840 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner Dragon game
Number of subjects: 500
Study 39475840 — intervention group
Group type: COMPARATOR
Intervention: Control (Smoke Free app core features)
Number of subjects: 500
Study 39475855 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional educational intervention covering healthy, sustainable nutrition and lifestyle.
Number of subjects: 227
Study 39475852 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Digital Behavior Change Intervention (DBCIs) including a scale, smartphone app, activity tracker, video library, and on-demand health coach.
Number of subjects: 603
Study 39475852 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Digital Behavior Change Intervention (DBCIs)
Number of subjects: 603
Study 39475852 — intervention group
Group type: COMPARATOR
Intervention: Standard employer-provided health and wellness benefits (Control)
Number of subjects: 603
Study 39475860 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Ingredient Supplement (MIS)
Number of subjects: 26
Study 39475860 — intervention group
Group type: COMPARATOR
Intervention: Collagen Control (COL)
Number of subjects: 26
Study 39475859 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body resistance exercise (RE) - 4 sets of 4 different exercises at 70% 1-repetition maximum with the last set to failure
Number of subjects: 16
Study 39475859 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body resistance exercise (RE)
Number of subjects: 16
Study 39475859 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (CON)
Number of subjects: 16
Study 39475960 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-, 11-, or 22-mg/day upadacitinib for 24 weeks
Number of subjects: 164
Study 39475960 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 164
Study 39475960 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-, 11-, or 22-mg/day upadacitinib
Number of subjects: 164
Study 39475960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 39475978 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D ultrasonography with 3D picture
Number of subjects: 33
Study 39475978 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D ultrasonography with 3D model
Number of subjects: 33
Study 39475978 — intervention group
Group type: COMPARATOR
Intervention: 3D ultrasonography (either intervention)
Number of subjects: 33
Study 39475978 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in cigarette use
Number of subjects: 33
Study 39476073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) targeting the prefrontal cortex, 5 days a week for 8 weeks followed by twice-a-year 5-day boosters and daily at-home CR.
Number of subjects: 375
Study 39476073 — intervention group
Group type: COMPARATOR
Intervention: Sham plus sham intervention.
Number of subjects: 375
Study 39476073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) targeting the prefrontal cortex.
Number of subjects: 375
Study 39476101 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombopoietin receptor agonists
Number of subjects: 48
Study 39476124 — intervention group
Group type: EXPERIMENTAL
Intervention: Forimtamig (GPRC5D-targeting T-cell bispecific antibody)
Number of subjects: 0
Study 39476124 — intervention group
Group type: EXPERIMENTAL
Intervention: Forimtamig in combination with standard-of-care agents (anti-CD38 antibodies, immunomodulatory drugs, proteasome inhibitors)
Number of subjects: 0
Study 39476124 — intervention group
Group type: EXPERIMENTAL
Intervention: Forimtamig in combination with novel therapeutic agents (BCMA-TCB and CELMoDs)
Number of subjects: 0
Study 39476204 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 29
Study 39476204 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Number of subjects: 29
Study 39476204 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance phase with CPX-351
Number of subjects: 29
Study 39476237 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Breakthrough Series (VBTS) intervention
Number of subjects: 11
Study 39476237 — intervention group
Group type: EXPERIMENTAL
Intervention: Site with lowest follow-up rate
Number of subjects: 11
Study 39476303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) alone
Number of subjects: 501
Study 39476303 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD) alone
Number of subjects: 501
Study 39476339 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous semaglutide (2.4 mg)
Number of subjects: 407
Study 39476339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study 39476340 — intervention group
Group type: EXPERIMENTAL
Intervention: Inavolisib plus palbociclib-fulvestrant
Number of subjects: 325
Study 39476340 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus palbociclib-fulvestrant
Number of subjects: 325
Study 39476340 — intervention group
Group type: EXPERIMENTAL
Intervention: Inavolisib
Number of subjects: 325
Study 39476340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 39476341 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Number of subjects: 109
Study 39476341 — intervention group
Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 109
Study 39476739 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic toothpaste containing Lactobacillus paracasei, used twice a day for four weeks.
Number of subjects: 44
Study 39476739 — intervention group
Group type: COMPARATOR
Intervention: Regular toothpaste (Colgate), used twice a day for four weeks.
Number of subjects: 44
Study 39476808 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling program for mothers based on UNICEF dietary guidelines, followed by monthly phone calls
Number of subjects: 516
Study 39476808 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 516
Study 39477026 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol's chromoendoscopy (LCE) + High-resolution microendoscopy (HRME)
Number of subjects: 916
Study 39477026 — intervention group
Group type: COMPARATOR
Intervention: Lugol's chromoendoscopy (LCE)
Number of subjects: 916
Study 39477171 — intervention group
Group type: EXPERIMENTAL
Intervention: IV rt-PA
Number of subjects: 3332
Study 39477171 — intervention group
Group type: COMPARATOR
Intervention: No IV rt-PA
Number of subjects: 3332
Study 39477187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Olaparib
Number of subjects: 851
Study 39477187 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab plus Placebo
Number of subjects: 851
Study 39477271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical intraepithelial neoplasia (CIN)2+ prevalence in women with HIV aged 30-49 (15.9%) vs 50+ (19.3%)
Number of subjects: 4090
Study 39477271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical intraepithelial neoplasia (CIN)2+ prevalence in women without HIV aged 30-49 (13.3%) vs 50+ (10.4%)
Number of subjects: 4090
Study 39477271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical intraepithelial neoplasia (CIN)3+ prevalence in women with HIV aged 30-49 vs 50+
Number of subjects: 4090
Study 39477271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical intraepithelial neoplasia (CIN)3+ prevalence in women without HIV aged 30-49 vs 50+
Number of subjects: 4090
Study 39477271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer diagnoses in women aged 50+
Number of subjects: 4090
Study 39477275 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodised salt fortified with 30 ppm folic acid to provide ~200 µg folic acid/day
Number of subjects: 360
Study 39477275 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodised salt fortified with 90 ppm folic acid to provide ~600 µg folic acid/day
Number of subjects: 360
Study 39477275 — intervention group
Group type: COMPARATOR
Intervention: Iodised salt (comparator)
Number of subjects: 360
Study 39477487 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR-enhanced programme
Number of subjects: 120
Study 39477487 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercise programme
Number of subjects: 120
Study 39477631 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care (SoC) therapy withdrawal
Number of subjects: 145
Study 39477631 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) therapy (not withdrawn)
Number of subjects: 145
Study 39477819 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home screening without provider encouragement
Number of subjects: 627
Study 39477819 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home screening with provider encouragement
Number of subjects: 627
Study 39477819 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic screening with provider encouragement
Number of subjects: 627
Study 39477819 — intervention group
Group type: COMPARATOR
Intervention: Clinic setting (control)
Number of subjects: 627
Study 39477819 — intervention group
Group type: EXPERIMENTAL
Intervention: White patients (all groups)
Number of subjects: 627
Study 39477835 — intervention group
Group type: EXPERIMENTAL
Intervention: APT-weighted imaging
Number of subjects: 9
Study 39477835 — intervention group
Group type: EXPERIMENTAL
Intervention: APT-weighted LD mapping
Number of subjects: 9
Study 39477835 — intervention group
Group type: COMPARATOR
Intervention: Conventional GTV
Number of subjects: 9
Study 39477924 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month rifapentine-moxifloxacin regimen
Number of subjects: 0
Study 39478168 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDAR1-abs seropositive patients
Number of subjects: 569
Study 39478450 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program based on Wellness Motivation Theory (WMT), performed three times a week for 24 weeks
Number of subjects: 144
Study 39478450 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program based on Wellness Motivation Theory (WMT)
Number of subjects: 144
Study 39478450 — intervention group
Group type: COMPARATOR
Intervention: One-time advice on physical activity
Number of subjects: 144
Study 39478521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine infusion (5 μg/kg/min) for 24 hours after PCI
Number of subjects: 100
Study 39478521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl) for 24 hours after PCI
Number of subjects: 100
Study 39478521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine infusion
Number of subjects: 100
Study 39478521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 100
Study 39478532 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily for 12 weeks, then open-label nintedanib for 12 weeks
Number of subjects: 0
Study 39478532 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks, then open-label nintedanib for 12 weeks
Number of subjects: 0
Study 39478532 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0
Study 39478532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39478564 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise oncology service
Number of subjects: 0
Study 39478609 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA with tourniquet
Number of subjects: 81
Study 39478609 — intervention group
Group type: COMPARATOR
Intervention: TKA without tourniquet
Number of subjects: 81
Study 39478644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohydroxyapatite (NHA)
Number of subjects: 24
Study 39478644 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone (DBB)
Number of subjects: 24
Study 39478672 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF + PegIFN
Number of subjects: 93
Study 39478672 — intervention group
Group type: COMPARATOR
Intervention: TDF alone
Number of subjects: 93
Study 39478814 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of home-based exercise and pulsed electromagnetic field (PEMF) therapy
Number of subjects: 60
Study 39478814 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise alone (control group)
Number of subjects: 60
Study 39479003 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute cerebrovascular dysfunction measured using multimodal non-invasive neuromonitoring (transcranial Doppler and cerebral near-infrared spectroscopy) within 7-days of onset of TBI.
Number of subjects: 130
Study 39479003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular dysfunction severity during acute phase.
Number of subjects: 130
Study 39479003 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery from cerebrovascular dysfunction.
Number of subjects: 130
Study 39479003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive/functional assessments (Glasgow Outcome Scale and Patient-Reported Outcomes Measurement Information System) at follow-ups 3-, 6-, and 12-months post-injury.
Number of subjects: 130
Study 39479005 — intervention group
Group type: EXPERIMENTAL
Intervention: 40Hz gamma sensory stimulation
Number of subjects: 0
Study 39479005 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 39479199 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye color (specific colors not mentioned)
Number of subjects: 0
Study 39479199 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39479329 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 111